SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Öhrfelt Annika 1973 ) "

Sökning: WFRF:(Öhrfelt Annika 1973 )

  • Resultat 11-20 av 32
  • Föregående 1[2]34Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
11.
  • Førland, Marthe Gurine, et al. (författare)
  • Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease.
  • 2018
  • Ingår i: Parkinsonism & related disorders. - 1873-5126. ; 49, s. 4-8
  • Tidskriftsartikel (refereegranskat)abstract
    • Cerebrospinal fluid (CSF) total α-synuclein is considered a potential biomarker for Parkinson's disease (PD), but little is known about the evolution of this marker during the course of the disease. Our objective was to investigate whether CSF total α-synuclein concentrations change over time and are associated with motor and cognitive function in PD.CSF total α-synuclein concentrations were quantified in 56 longitudinally followed PD patients, 27 of whom provided CSF repeatedly 2 and/or 4 years later. Another 18 subjects were included as controls. The samples were analyzed using two independent, validated ELISA methods: our recently developed and validated in-house ELISA and a commercial kit from BioLegend.CSF total α-synuclein levels did not distinguish PD patients from controls, displayed no substantial changes during a period of up to 4 years, and did not predict subsequent motor or cognitive decline. These findings were consistent for both analytical methods.Our findings do not support the clinical utility of total α-synuclein as a single diagnostic or prognostic biomarker in PD.
  •  
12.
  • Førland, Marthe Gurine, et al. (författare)
  • Validation of a new assay for α-synuclein detection in cerebrospinal fluid.
  • 2017
  • Ingår i: Clinical chemistry and laboratory medicine. - 1437-4331. ; 55:2
  • Tidskriftsartikel (refereegranskat)abstract
    • Abnormal α-synuclein aggregation and deposition is the pathological hallmark of Parkinson's disease (PD) and dementia with Lewy bodies (DLB), but is also found in Alzheimer disease (AD). Therefore, there is a gaining interest in α-synuclein in cerebrospinal fluid (CSF) as potential biomarker for these neurodegenerative diseases. To broaden the available choices of α-synuclein measurement in CSF, we developed and validated a new assay for detecting total α-synuclein.
  •  
13.
  • Hall, Sara, et al. (författare)
  • Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
  • 2012
  • Ingår i: Archives of neurology. - 1538-3687. ; 69:11, s. 1445-52
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: To assess the ability of 5 cerebrospinal fluid (CSF) biomarkers to differentiate between common dementia and parkinsonian disorders. Design: A cross-sectional, clinic-based study. Participants: Cerebrospinal fluid samples (N=453) were obtained from healthy individuals serving as controls and from patients with Parkinson disease (PD), PD with dementia (PDD), dementia with Lewy bodies (DLB), Alzheimer disease (AD), progressive supranuclear palsy (PSP), multiple system atrophy (MSA), or corticobasal degeneration (CBD). Setting: Neurology and memory disorder clinics. Main Outcome Measures: Cerebrospinal fluid biomarker levels in relation to clinical diagnosis. Results: Cerebrospinal fluid levels of alpha-synuclein were decreased in patients with PD, PDD, DLB, and MSA but increased in patients with AD. Cerebrospinal fluid levels of beta-amyloid 1-42 were decreased in DLB and even further decreased in AD. Cerebrospinal fluid levels of total tau and hyperphosphorylated tau were increased in AD. Multivariate analysis revealed that these biomarkers could differentiate AD from DLB and PDD with an area under the curve of 0.90, with alpha-synuclein and total tau contributing most to the model. Cerebrospinal fluid levels of neurofilament light chain were substantially increased in atypical parkinsonian disorders (ie, PSP, MSA, and CBD), and multivariate analysis revealed that the level of neurofilament light chain alone could differentiate PD from atypical parkinsonian disorders, with an area under the curve of 0.93. Conclusions: Ascertainment of the alpha-synuclein level in CSF somewhat improves the differential diagnosis of AD vs DLB and PDD when combined with established AD biomarkers. The level of neurofilament light chain alone may differentiate PD from atypical parkinsonian disorders.
  •  
14.
  • Hall, Sara, et al. (författare)
  • CSF biomarkers and clinical progression of Parkinson disease.
  • 2015
  • Ingår i: Neurology. - American Academy of Neurology. - 1526-632X. ; 84:1, s. 57-63
  • Tidskriftsartikel (refereegranskat)abstract
    • To investigate whether certain CSF biomarkers at baseline can predict future progression of motor symptoms and cognitive decline in patients with Parkinson disease (PD).
15.
16.
  • Nazir, Faisal Hayat, et al. (författare)
  • Expression and secretion of synaptic proteins during stem cell differentiation to cortical neurons.
  • 2018
  • Ingår i: Neurochemistry international. - 1872-9754. ; 121, s. 38-49
  • Tidskriftsartikel (refereegranskat)abstract
    • Synaptic function and neurotransmitter release are regulated by specific proteins. Cortical neuronal differentiation of human induced pluripotent stem cells (hiPSC) provides an experimental model to obtain more information about synaptic development and physiology in vitro. In this study, expression and secretion of the synaptic proteins, neurogranin (NRGN), growth-associated protein-43 (GAP-43), synaptosomal-associated protein-25 (SNAP-25) and synaptotagmin-1 (SYT-1) were analyzed during cortical neuronal differentiation. Protein levels were measured in cells, modeling fetal cortical development and in cell-conditioned media which was used as a model of cerebrospinal fluid (CSF), respectively. Human iPSC-derived cortical neurons were maintained over a period of at least 150 days, which encompasses the different stages of neuronal development. The differentiation was divided into the following stages: hiPSC, neuro-progenitors, immature and mature cortical neurons. We show that NRGN was first expressed and secreted by neuro-progenitors while the maximum was reached in mature cortical neurons. GAP-43 was expressed and secreted first by neuro-progenitors and its expression increased markedly in immature cortical neurons. SYT-1 was expressed and secreted already by hiPSC but its expression and secretion peaked in mature neurons. SNAP-25 was first detected in neuro-progenitors and the expression and secretion increased gradually during neuronal stages reaching a maximum in mature neurons. The sensitive analytical techniques used to monitor the secretion of these synaptic proteins during cortical development make these data unique, since the secretion of these synaptic proteins has not been investigated before in such experimental models. The secretory profile of synaptic proteins, together with low release of intracellular content, implies that mature neurons actively secrete these synaptic proteins that previously have been associated with neurodegenerative disorders, including Alzheimer's disease. These data support further studies of human neuronal and synaptic development in vitro, and would potentially shed light on the mechanisms underlying altered concentrations of the proteins in bio-fluids in neurodegenerative diseases.
  •  
17.
  • Nutu, Magdalena, et al. (författare)
  • Evaluation of the Cerebrospinal Fluid Amyloid-beta(1-42)/Amyloid-beta(1-40) Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders
  • 2013
  • Ingår i: Dementia and Geriatric Cognitive Disorders. - Karger. - 1420-8008. ; 36:1-2, s. 99-110
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: The well-established core biomarkers used to identify Alzheimer's disease (AD) overlap with other dementia disorders such as dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD). This study aimed to evaluate whether the cerebrospinal fluid (CSF) amyloid-beta (A beta)(1-42)/A beta(1-40) ratio, measured by a novel method, could improve the differential diagnosis of AD, DLB and PDD. Method: CSF levels of A beta(1-40) and A beta(1-42) in patients with PDD, DLB, AD, Parkinson's disease and controls were analyzed using an amplified luminescent proximity homogenous immunoassay along with conventional immunoassays. Results: The CSF A beta(1-42)/A beta(1-40) ratio increased discrimination of AD from PDD and DLB compared with either of the two A beta biomarkers individually. Conclusion: The use of the A beta(1-42)/A beta(1-40) ratio could improve the differentiation of AD from PDD and DLB. (C) 2013 S. Karger AG, Basel
  •  
18.
  • Portelius, Erik, 1977-, et al. (författare)
  • Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid.
  • 2010
  • Ingår i: Experimental neurology. - 1090-2430. ; 223:2, s. 351-358
  • Tidskriftsartikel (refereegranskat)abstract
    • Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system. Two pathological hallmarks in the brain of AD patients are neurofibrillary tangles and senile plaques. The plaques consist mainly of beta-amyloid (Abeta) peptides that are produced from the amyloid precursor protein (APP), by sequential cleavage by beta- and gamma-secretase. Most previous studies have been focused on the C-terminal fragments of APP, where the Abeta sequence is localized. The purpose of this study was to search for N-terminal fragments of APP in cerebrospinal fluid (CSF) using mass spectrometry (MS). By using immunoprecipitation (IP) combined with matrix-assisted laser desorption/ionization time-of-flight MS as well as nanoflow liquid chromatography coupled to high resolution tandem MS we were able to detect and identify six novel N-terminal APP fragments [APP((18-119)), APP((18-121)), APP((18-122)), APP((18-123)), APP((18-124)) and APP((18-126))], having molecular masses of approximately 12 kDa. The presence of these APP derivatives in CSF was also verified by Western blot analysis. Two pilot studies using either IP-MS or Western blot analysis indicated slightly elevated levels of N-terminal APP fragments in CSF from AD patients compared with controls, which are in need of replications in independent and larger patient materials.
  •  
19.
  •  
20.
  • Trupp, Miles, et al. (författare)
  • Metabolite and Peptide Levels in Plasma and CSF Differentiating Healthy Controls from Patients with Newly Diagnosed Parkinson's Disease.
  • 2014
  • Ingår i: Journal of Parkinson's disease. - 1877-718X. ; 4:3, s. 549-560
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Parkinson's disease (PD) is a progressive, multi-focal neurodegenerative disease for which there is no effective disease modifying treatment. A critical requirement for designing successful clinical trials is the development of robust and reproducible biomarkers identifying PD in preclinical stages. Objective: To investigate the potential for a cluster of biomarkers visualized with multiple analytical platforms to provide a clinically useful tool. Methods: Gas Chromatography-Mass Spectrometry (GC-TOFMS) based metabolomics and immunoassay-based protein/peptide analyses on samples from patients with PD diagnosed in Northern Sweden. Low molecular weight compounds from both plasma and cerebrospinal fluid (CSF) from 20 healthy subjects (controls) and 20 PD patients at the time of diagnosis (baseline) were analyzed. Results: In plasma, we found a significant increase in several amino acids and a decrease in C16-C18 saturated and unsaturated fatty acids in patients as compared to control subjects. We also observed an increase in plasma levels of pyroglutamate and 2-oxoisocaproate (ketoleucine) that may be indicative of increased metabolic stress in patients. In CSF, there was a generally lower level of metabolites in PD as compared to controls, with a specific decrease in 3-hydroxyisovaleric acid, tryptophan and creatinine. Multivariate analysis and modeling of metabolites indicates that while the PD samples can be separated from control samples, the list of detected compounds will need to be expanded in order to define a robust predictive model. CSF biomarker immunoassays of candidate peptide/protein biomarkers revealed a significant decrease in the levels of Aβ-38 and Aβ-42, and an increase in soluble APPα in CSF of patients. Furthermore, these peptides showed significant correlations to each other, and positive correlations to the CSF levels of several 5- and 6-carbon sugars. However, combining these metabolites and proteins/peptides into a single model did not significantly improve the statistical analysis. Conclusions: Together, this metabolomics study has detected significant alterations in plasma and CSF levels of a cluster of amino acids, fatty acids and sugars based on clinical diagnosis and levels of known protein and peptide biomarkers.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 11-20 av 32
  • Föregående 1[2]34Nästa
Åtkomst
fritt online (4)
Typ av publikation
tidskriftsartikel (30)
bokkapitel (1)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (32)
övrigt vetenskapligt (1)
Författare/redaktör
Blennow, Kaj, 1958-, (23)
Zetterberg, Henrik, ... (21)
Öhrfelt, Annika, 197 ... (19)
Brinkmalm-Westman, A ... (9)
Brinkmalm, Gunnar, (9)
Hansson, Oskar, (7)
visa fler...
Brinkmalm, Ann, (7)
Zetterberg, Henrik, (6)
Wallin, Anders, 1950 ... (6)
Ohrfelt, Annika (6)
Minthon, Lennart, (5)
Blennow, Kaj (5)
Portelius, Erik, 197 ... (4)
Andreasson, Ulf, 196 ... (4)
Vanmechelen, Eugeen (4)
Bjerke, Maria, 1977- ... (4)
Londos, Elisabet, (3)
Blennow, K (3)
Vanmechelen, E (3)
Nägga, Katarina, (3)
Hall, Sara (3)
Zetterberg, H (2)
Wallin, A (2)
Rolstad, Sindre, 197 ... (2)
Olsson, Bob, 1969-, (2)
Forsgren, Lars, (2)
Linder, Jan, (2)
Tysnes, Ole Bjørn, (2)
Svensson, Johan, 196 ... (2)
Alves, Guido (2)
Lange, Johannes (2)
Andreasen, Niels, (2)
Andreasen, N, (2)
Nordlund, Arto, 1962 ... (2)
Bhattacharjee, Payel ... (2)
Edman, Åke, (2)
Jonsson, Michael, 19 ... (2)
Eckerström, Carl, (2)
Andreasson, Ulf, (2)
Gobom, Johan, (2)
Honer, William G. (2)
Sjödin, Simon, (2)
Persson, Rita, 1951- ... (2)
Nutu, Magdalena (2)
Olsson, Erik, 1960-, (2)
Trupp, Miles (2)
Eckerström, Marie, 1 ... (2)
Göthlin, Mattias, 19 ... (2)
Førland, Marthe Guri ... (2)
Surova, Yulia, (2)
visa färre...
Lärosäte
Göteborgs universitet (32)
Lunds universitet (7)
Karolinska Institutet (3)
Språk
Engelska (32)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (32)
Naturvetenskap (1)
Teknik (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy